A

Amgen

Makes biotech medicines for serious illnesses

Information Security Architect - Encryption Agility Team

Full-TimeUpdated on 10/24/2026
No salary listed
Expert
Bachelor's, Master's, PhD
Hyderabad, Telangana, India
In PersonOn-site in Hyderabad, India.
CybersecuritySecurity Engineering & Architecture

About the job

Requirements
  • Doctorate degree and 2 years of experience in Information Security, Cybersecurity, Cryptography, Security Architecture, Computer Science, Information Technology, Engineering, or related experience; or master's degree with 8 to 10 years of such experience; or bachelor's degree with 10 to 14 years of such experience; or diploma with 14 to 18 years of such experience.
  • Expert hands-on knowledge of enterprise cryptography and security architecture, including Public Key Infrastructure (PKI), X.509 certificates, Transport Layer Security (TLS), cipher suites, Key Management Services (KMS), Hardware Security Modules (HSMs), secrets management, key lifecycle, encryption at rest and in transit, cloud key services, identity protocols, and certificate lifecycle automation.
  • Practical experience architecting cryptographic modernization, crypto agility, post-quantum cryptography, hybrid transition patterns, discovery-to-remediation workflows, Cryptographic Bill of Materials (CBOM)-driven inventory, and Steal-Now-Decrypt-Later risk reduction in a complex enterprise environment.
  • Ability to translate cryptographic policy and standards into enforceable technical controls across Continuous Integration/Continuous Delivery (CI/CD), Secure Software Development Life Cycle (SSDLC), cloud platforms, PKI/certificates, KMS/secrets, identity, infrastructure, applications, third-party governance, and risk management.
  • Ability to perform hands-on analysis of cryptographic discovery findings, source code patterns, certificate chains, TLS/cipher data, cloud key configurations, key rotation status, secrets exposure, and architecture designs, and convert findings into practical remediation guidance.
  • Certified Information Systems Security Professional (CISSP) certification is required.
Responsibilities
  • Serve as the Principal Architect and senior technical authority for the Encryption Agility Service, partnering with the Senior Manager to define the technical roadmap, architecture backlog, design guardrails, quality expectations, and enterprise architecture direction for Post-Quantum Cryptography (PQC) readiness.
  • Develop enterprise target-state architecture for encryption, cryptography, crypto agility, and PQC readiness across applications, cloud, infrastructure, identity, PKI, KMS, certificates, secrets, data protection, Software as a Service (SaaS), third-party ecosystems, and related security configuration baselines.
  • Translate National Institute of Standards and Technology (NIST) PQC standards and related guidance into reference architectures, secure patterns, technology standards, security configuration baselines, engineering guidance, and a CBOM operating model and data architecture, including required fields, source systems, ownership attributes, quantum-vulnerability and remediation status, data quality checks, reporting views, Software Bill of Materials (SBOM) alignment, subject matter expert interview inputs, and CycloneDX 1.6+ alignment.
  • Define cryptographic discovery architecture, tool integration requirements, and technical evaluation criteria across source code, binaries, cloud key services, endpoints, file systems, network traffic, PKI and certificates, KMS and secrets, vendor attestations, SBOMs, Governance, Risk, and Compliance (GRC), Security Information and Event Management (SIEM)/data lake, and cryptographic discovery platforms.
  • Partner with Digital Identity Access Services (DIAS), PKI service owners, certificate management teams, identity teams, cloud, infrastructure, and platform teams on certificate visibility, Certificate Lifecycle Management (CLM) requirements, Microsoft PKI, Sectigo, AWS Certificate Manager (ACM), AWS Private Certificate Authority, hybrid certificate testing, Certificate Authority modernization, operational change windows, enterprise KMS strategy, HSM patterns, secrets management, key lifecycle policy, key rotation and retirement, storage standards, ownership, reporting, and centralized or federated controls.
  • Design remediation and crypto-agility patterns for hybrid TLS, proxy-based crypto agility, network encapsulation, Internet Protocol Security (IPsec), Media Access Control Security (MACsec), Key Management Interoperability Protocol (KMIP), Public-Key Cryptography Standard (PKCS), provider and custom code libraries, symmetric cryptography, Hash-Based Message Authentication Code (HMAC), legacy and unchangeable applications, TLS termination, reverse proxies, encrypted overlays, segmentation controls, compensating controls, and risk-based replacement or decommission pathways.
  • Provide hands-on technical review of cryptographic scan outputs, source code findings, certificate chains, cipher suite configurations, Secure Shell (SSH) settings, Open Authorization (OAuth), Security Assertion Markup Language (SAML), JSON Web Token (JWT) patterns, cloud key configurations, CBOM data, key and secret storage, and other cryptographic implementation patterns.
  • Partner with Application Security, Artificial Intelligence (AI) Security, Enterprise Architecture, DevOps, and engineering teams to publish approved cryptographic libraries, secure code examples, reusable patterns, CI/CD controls, SSDLC requirements, scanning rules, developer remediation playbooks, and guidance for data at rest and in transit, identity protocols, Application Programming Interfaces (APIs), certificates, secrets, key stores, service-to-service communication, external data exchanges, and high-value sensitive data flows.
  • Apply the approved quantum risk-prioritization approach to sequence discovery and remediation for business-critical applications, high-volume sensitive data flows, third-party dependencies, identity services, legacy platforms, Key Computerized Systems (KCS), validated/Good Practice (GxP) systems, and Operational Technology (OT) scope; lead architecture and design reviews for PQC pilots and trials, including test environments, hybrid TLS testing, PQ-PKI experiments, cryptographic discovery proofs of concept, CLM/KMS evaluations, algorithm interoperability, performance impact, and rollout readiness.
  • Support vendor, third-party, OT, and manufacturing architecture governance with Procurement, Legal, Risk and Compliance, Third Party Risk Management (TPRM), business owners, and site stakeholders by defining technical questionnaire content, CBOM requests, evidence expectations, roadmap review criteria, contract language inputs, escalation triggers, passive-only discovery assumptions, vendor firmware roadmaps, boundary architecture, validated system impacts, revalidation planning, and ownership handoffs where remediation remains outside the Encryption Agility Service.
  • Maintain and refresh cryptographic architecture artifacts, Security Configuration Baselines (SCBs), Standard Operating Procedures (SOPs), technical standards, exception patterns, remediation decision trees, and implementation guides; provide top-level technical escalation for architecture exceptions, discovery tool gaps, false-positive triage, certificate lifecycle risks, key management patterns, protocol and cipher decisions, vendor evidence gaps, and complex remediation tradeoffs.
  • Mentor Global Career Framework level 5 (L5) and level 4 (L4) engineers, analysts, and contributors, and monitor guidance from the Internet Engineering Task Force (IETF), National Security Agency Commercial National Security Algorithm Suite 2.0 (NSA CNSA 2.0), International Organization for Standardization (ISO), Health Insurance Portability and Accountability Act (HIPAA), Health Information Trust Alliance (HITRUST), and broader cryptography guidance to translate changes into architecture decisions and backlog items.
Desired Qualifications
  • Hands-on experience with ServiceNow CMDB/GRC, Guard, Wiz, Qualys, Fortinet, Netskope, CrowdStrike, GitLab, Veracode, GitGuardian, AWS KMS, AWS ACM, AWS Secrets Manager, Microsoft PKI, Sectigo, HashiCorp Vault, HSMs, CLM platforms, and SIEM/data lake integrations.
  • Experience designing or operating CBOM/SBOM data models using CycloneDX 1.6+, APIs, Comma-Separated Values (CSV), JavaScript Object Notation (JSON), dashboards, data quality controls, and audit-ready reporting.
  • Experience designing PKI modernization, certificate automation, certificate rotation, Certificate Authority hierarchy changes, hybrid certificate testing, and PQ-PKI transition plans.
  • Experience designing key management and secrets management architecture across AWS, Azure, on-premises platforms, HSMs, Vault technologies, automation workflows, and centralized or federated operating models.
  • Experience with application security, DevSecOps, SSDLC governance, CI/CD quality gates, approved cryptographic libraries, static analysis, dynamic analysis, composition analysis, and developer enablement.
  • Experience in pharmaceutical, life sciences, regulated, validated, GxP, KCS, manufacturing, OT, or other change-controlled environments where architecture changes may trigger validation or quality review.
  • Experience with vendor and third-party risk management, supplier cryptographic questionnaires, contract requirement inputs, roadmap evidence review, SaaS platform dependencies, and vendor escalation.
  • Scripting and automation experience with Python, PowerShell, Bash, REST APIs, data pipelines, parsing certificate or scan data, or lightweight integration development.
  • CISM, CISA, or CRISC certification.
  • CCSP, AWS Certified Security - Specialty, Microsoft Azure Security Engineer, or equivalent cloud security certification.
  • TOGAF or SABSA certification.
  • ITIL, SAFe, product management, program management, or equivalent delivery certification.
  • Relevant PKI, KMS, HSM, cryptographic discovery, certificate lifecycle management, cloud key management, or post-quantum cryptography training or certification.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.